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Abstract
Keratoconjunctivitis sicca (KCS), or dry eye, is a significant medical problem in both humans and dogs. Treating KCS often
requires the daily application of more than one type of eye drop in order to both stimulate tear prodcution and provide a
tear supplement to increase hydration and lubrication. A previous study demonstrated the potential for a crosslinked
hyaluronic acid-based hydrogel (xCMHA-S) to reduce the clinical signs associated with KCS in dogs while using a reduced
dosing regimen of only twice-daily administration. The present study extended those results by comparing the use of the
xCMHA-S to a standard HA-containing tear supplement in a masked, randomized clinical study in dogs with a clinical
diagnosis of KCS. The xCMHA-S was found to significantly improve ocular surface health (conjunctival hyperaemia, ocular
irritation, and ocular discharge) to a greater degree than the alternative tear supplement (P= 0.0003). Further, owners
reported the xCMHA-S treatment as being more highly effective than the alternative tear supplement (P= 0.0024). These
results further demonstrate the efficacy of the xCMHA-S in reducing the clinical signs associated with KCS, thereby
improving patient health and owner happiness.
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Introduction
Dry eye or keratoconjunctivitis sicca (KCS), is a widespread
problem in both the human and canine populations. The
prevalence of KCS in humans may vary between 5 and 33%, in
different reports and with different methods of ocular evaluation
[1]. The prevalence in the canine species varies between 1 to 4%
[2]. Topical cyclosporine has been developed as a widely
efficacious lacrimogenic agent in dogs [3] and more recently in
man, [4] but not all individuals in either affected population
respond adequately to the drug by a higher rate of tear production.
Also, the high price of the product puts it out of the financial reach
of many dog owners. For these reasons an effective, less expensive
tear replacement eyedrop is still required. Many of these are
available as topical medications containing a wide number of
lubricating agents, including polyacrylic acid, polyvinyl alcohol,
and hyaluronic acid (HA) [2,5]. Since HA is a naturally occurring
polysaccharide found as a lubricative agent in joint fluid, its use as
a similar agent on the ocular surface is particularly appropriate
[6,7]. For tear supplements containg HA, previous reports have
shown that the viscoelasticity of the polysaccharide leads to an
increase in tear stability and a consequent reduction in many of
the symptoms of dry eye [8–10].
The viscoelasticity of HA-based products can vary significantly,
depending on the molecular weight and concentration of the HA
used, as well as the concentration of salts present due to interaction
with the polyanionic HA [8,11,12]. Such variation in rheologic
properties, such as viscoelasticity, can lead to differences in
comfort and efficacy for a dry eye formulation [13]. Typical HA-
based tear supplements have been a simple solution of high
molecular weight, low concentration HA. However, by covalently
crosslinking HA, such as the formulation documented herein,
leads to a more viscoelastic material. This increase in viscoelas-
ticity extends the contact time of the HA with the ocular surface
and will thus allow for less frequent application, reducing the
overall cost and burden on the patient, and in the case of dogs, the
owner. The covalent HA crosslinking described here, acts in a
different manner than the physical or ionic crosslinking occurring
in solutions of simple high molecular weight HA.
The crosslinked modified HA, thiolated carboxymethyl HA
(CMHA-S), used in the present study has previously been used in
other formulations to treat skin and corneal wounds [14,15]. The
hydrogel formulation used in this study was specifically developed
as a tear supplement for the treatment of canine KCS. We have
previously characterised the hydrogel rheologically to compare
with non-crosslinked solutions of HA [16]. We also compared the
ocular surface effects of this product to a previous study using a
different tear replacement drop, evaluating tear production by use
of the Schirmer tear test, conjunctival hyperaemia, ocular
discharge and ocular irritation as determined by blink frequency
and palpebral apperture narrowing [17]. Although the previous
study demonstrated promising results, it was neither masked nor
randomised, and the comparison of the products relied on two
populations of KCS-affected dogs. Here we present the results of a
study in which KCS-affected dogs were randomly assigned to
treatment with either the CMHA-S product or a commercial tear
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replacement drop. Importantly, the medication was dispensed in
such a manner that the investigator could not know which
medication was being provided. Only after completion of the study
and all assessments made following medication was the treatment
regime for each dog unmasked, thus allowing a truly masked
study. The statistical analyses of the data were also blinded in that
statisticians were provided only ‘‘treatment one’’ and ‘‘treatment
two’’ identification for each dog.
Materials and Methods
Crosslinked CMHA-S hydrogel
CMHA-S was synthesized and analyzed as previously described
[15,16]. A CMHA-S solution was then filter-sterilized, crosslinked
to form a hydrogel, and packaged aseptically into sterile 10-ml eye
drop bottles as previously described [16].
Animals
The study was reviewed and accepted by the Ethics and Welfare
Committee of the Department of Veterinary Medicine, University
of Cambridge, Cambridge, UK and all animals were treated in
accordance with the welfare guidelines in the Royal College of
Veterinary Surgeons Guide to Professional Conduct.
Twenty dogs affected with KCS (as diagnosed clinically) and for
whom treatment with topical cyclosporine (Optimmune, Schering-
Plough UK) was either ineffective or not available for financial
reasons were entered into the study with full informed owner
consent. The gender, breed, and age of the dogs in the study is
given in Table 1.
Clinical evaluation and treatment
All dogs underwent full clinical and ophthalmic examination
using a direct and indirect ophthalmoscopy and slit lamp
biomicroscopy. Tear production was measured using the Schirmer
tear test and ocular surface health assessed with the clinical
measurements of conjunctival hyperaemia, ocular discharge and
ocular irritation, graded as absent (0), mild (1), moderate (2) or
severe (3). Tear supplement, either the crosslinked modified HA
product (xCMHA-S) or the HA-based iDropH Vet Plus Eye
Lubricant (ITRD; I-MED Animal Health), was dispensed without
the investigator being made aware of the treatment given. Dogs
were treated for three weeks before reassessment. Owners were
requested to use the trial medication alone three times daily. On
re-examination a full ophthalmic examination was undertaken
with conjunctival hyperaemia, ocular discharge and ocular
irritation assessed and graded as previously. Owners were asked
for their own subjective assessment of whether the treatment given
was effective in ameliorating their animal’s ocular symptoms,
rating this from not effective (0) to highly effective (3).
The number of dogs included in the study was determined by a
power analysis [18]. Using a desired effect size (the difference in
mean between the treatment groups) for the composite score of
2.5, a standard deviation of 1.9 (based on the previous prospective
study [16]), a type I error of 0.05, and power of 0.8, a sample size
needed for each treatment group was 10.
Table 1. Demographics and composite pre-treatment and post-treatment scores of ocular health for xCMHA-S and ITRD
treatment of 10 dogs each.
Dog ID# Breed Age Sex/neuter Pre-score Post-score
xCMHA-S Treatment
601 Boxer 12 fn 6 1
606 WHWT 6 fn 14 5
608 JRT 11 fe 4 2
609 WHWT 12 fn 9 0
610 CKCS 9 fn 6 0
611 Shih Tzu 8 mn 4 0
614 ECS 12 fn 15 2
615 ACS 9 me 9 0
617 CKCS 10 fn 10 4
618 WHWT 12 fn 11 2
ITRD Treatment
602 WHWT 7 fn 11 6
603 Lhasa Apso 8 me 6 3
604 CKCS 5 mn 9 4
605 CKCS 7 fn 9 3
607 X-bred 8 fn 8 3
612 X-bred 12 me 12 6
613 Labrador 10 fn 6 3
616 Lhasa Apso 8 fe 13 8
619 Cairn terrier 14 fe 14 6
620 ECS 9 mn 10 7
In Breed: WHWT = West Highland white terrier; JRT = Jack Russell terrier; CKCS = Cavalier King Charles spaniel; ECS = English cocker spaniel; ACS = American cocker
spaniel; X-bred = mixed breed. In Gender: Fn = neutered female; Fe = unaltered female; Mn = neutered male; Me = unaltered male.
doi:10.1371/journal.pone.0099766.t001
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Statistical analysis
The primary outcome was defined as the composite post-
treatment score, as the sum of the six post-treatment scores for
each dog (hyperaemia, irritation, and discharge for each eye). This
score was compared with the composite pre-treatment score using
an analysis of covariance (ANCOVA) with the post-treatment
score as the dependent variable, treatment as the main effect and
pre-treatment score as the covariate. The pre-treatment score was
used as a covariate because dogs that started with low scores
cannot improve to the same extent as can dogs starting with higher
scores, and thus improvement depends to some degree on the pre-
treatment scores. A two-tailed t-test was used to compare the
average age of dogs in the two groups, as well as owner happiness
after treatment for the two groups. As previously mentioned,
statistical analyses were made with the statistician blinded to the
treatment given.
Results
The treatment provided to each dog is shown in Table 1
together with composite pre-treatment and post-treatment scores.
Dogs of a range of species were included with breeds predisposed
to KCS such as West Highland White terriers, Lhasa Apsos, Shih
Tzus, Cocker Spaniels and Cavalier King Charles spaniels
predominating. The genders of the dogs were 7 female neutered
animals, one entire bitch, one entire dog and one neutered dog in
the xCHMA-S arm and 4 female neutered animals, two entire
bitches, two entire dogs and one neutered dog in the ITRD arm of
the study. The average age of dogs in the xCHMA-S arm
(10.162.1 years) was not significantly different than in the ITRD
arm (8.862.6 years) (P=0.23).
Pre-treatment and post-treatment scores for STT, hyperaemia,
irritation, and discharge for each dog are provided in Table 2,
along with the owner happiness ratings at the end of the treatment
period. Figure 1 shows the difference between pre-treatment and
post-treatment composite scores for all dogs, demonstrating that
xCHMA-S gives a substantially better resolution of KCS-
associated ocular surface signs than does ITRD. The linear fits
are forced through the origin, as no improvement is expected for
cases with pre-scores of 0. For both treatments, the trends of the
post-treatment scores are roughly proportional to the pre-
treatment scores. There was no significant increase in STT
following treatment with either xCMHA-S or ITRD (right eye:
P=0.1773 for both treatments; left eye: P=0.5086 for xCMHA-S,
0.2695 for ITRD). Additionally, there was no significant difference
between treatment groups for post-treatment STT, using pre-
treatment STT as a covariate (right eye: P=0.9445; left eye:
P=0.6170).
Table 3 provides the ANCOVA p-value for composite scores,
showing that the coefficient for treatment, adjusted for pre-
treatment scores, is highly significant (P=0.0003). These results
indicate that xCHMA-S treatment significantly improved com-
posite ocular surface health compared to ITRD treatment. The
adjustment for pre-score was also highly significant (P=0.0018).
The effects of age, sex, and neuter status were also tested, but were
not found to be significant (P=0.4405, 0.6298, and 0.3841,
respectively). Additionally, a test of the slopes in Figure 1 indicated
that they were highly significantly different (P=0.00006). The
post-scores for ITRD treatment were higher than the post-scores
for xCMHA-S treatment, despite accounting for differences in pre-
scores between the two treatments.
ANCOVA analysis was performed on each of the six assessment
criteria as well, and the resulting P-values are also shown in
Table 3. Conjunctival hyperaemia and degree of irritation show
statistically significantly greater improvement with xCMHA-S
treatment than ITRD treatment, although the degree of irritation
result for the right eye is not significant with the Bonferroni
adjustment for multiple testing. The amount of discharge was not
significantly different, likely because it is a much more variable
clinical sign than conjunctival hyperaemia or ocular irritation. In
fact, several dogs had low discharge scores pre-treatment in both
groups, leading to this non-significant difference. The eyes are
shown separately since conflating the results in eyes in which
Figure 1. Composite score results. Post-treatment composite score plotted against pre-treatment composite score for xCMHA-S and ITRD
treatments for all 20 dogs in the study. Note that for xCMHA-S, 2 dogs had a pre-treatment composite of 9 and post-treatment composite of 0; for
ITRD, 2 dogs had a pre-treatment composite of 6 and post-treatment composite of 3. Lines indicate linear fits for each treatment.
doi:10.1371/journal.pone.0099766.g001
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clinical signs are likely to be correlated would give inappropriately
elevated degrees of significance [19].
Owner happiness with the results of treatment was significantly
higher with xCHMA-S treatment than with ITRD (P=0.0024).
For xCMHA-S treatment, the average score was 2.860.4, with
eight of the 10 owners rating the treatment as highly effective
(score of 3). For ITRD treatment, the average score was 1.860.8,
with only two of the 10 owners rating the treatment as highly
effective.
Discussion
Treatment for dry eye (KCS) can be taxing, whether in canine
patients or humans. The advent of topical cyclosporine has
substantially improved the lot of individuals in which this
treatment is effective, but there are dogs in which the medication
does not have the desired lacrimomimetic effects and for many
owners the drug is too expensive, given as it must be used for the
lifetime of the animal. Yet regular treatment with topical tear
replacers can be difficult for owner and pet, and for human
patients also.
In a previous study we reported the use of a crosslinked HA-
based hydrogel as a tear supplement in a clinical study of 25 dogs
with KCS [16]. Although the study demonstrated the potential for
the xCMHA-S to reduce the clinical signs associated with KCS,
the study was not masked or randomized. Thus, here we
conducted a masked, randomized study comparing the
xCMHA-S hydrogel and a standard tear replacement eye drop
containing HA.
The results show a statistically significantly better therapeutic
efficacy, based on ocular surface health, with the xCMHA-S gel
applied three times daily than with the standard tear replacement
drop. ANCOVA analysis was necessary here, with the pre-
treatment score as a covariate, since the pre-treatment score will
affect the degree to which the score can improve. Because the pre-
treatment score estimate is not equal to 1.0, it underlines the idea
that the treatment cannot have the same effect if a component of
the composite pre-treatment score is coded as 0 as it can if that
component is coded 3.
Although ocular surface health was improved, there was no
significant improvement in STT value with either treatment. This
was expected since both types of drops are merely tear
supplements and do not stimulate the production of tears [16].
Additionally, owners were happier with the outcome of using the
xCMHA-S gel compared to the standard tear replacement drop.
Since this clinical study involved canine patients, it was not
possible to assess any potential disruption in vision due to the
increased viscosity of the xCMHA-S gel compared to the ITRD
drops. However, if the owners had observed any vision issues, it is
likely that the owner happiness scores would have been lower.
These findings have important implications for the canine
population where an effective ocular surface lubricant will be
welcomed by owners and canine patients alike. This crosslinked
CMHA-S hydrogel may have potential translational importance as
well, as an effective tear replacement drop with a long ocular
surface residence time and thus a low required dose frequency
would be highly valuable for the sizeable population of humans
with dry eye.
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